Explore more
News
FDA Will Ask Sarepta to Halt Gene Therapy Shipments
Digest more
The FDA will request Sarepta Therapeutics stop all shipments of Elevidys, its gene therapy for Duchenne muscular dystrophy, ...
The restructuring enacted by Sarepta Therapeutics is expected to save up to $400 million in annual costs. Read why I'm ...
Three patients with a muscle-wasting disease died from liver failure after taking the therapy, Elevidys, or a similar ...
As mothers of children with this disease, we have wept helplessly in recent months as friends — fellow members of a club we ...
Stocks traded mixed Friday as investors focused on corporate earnings, a day after the S&P 500 and Nasdaq Composite set ...
CNBC's Angelica Peebles joins 'Squawk on the Street' with the latest news on Sarepta following a patient death.
Stocks on Sky High. Sarepta Therapeutics, Inc. (NASDAQ:SRPT) is one of the top-performing companies on Thursday. Sarepta Therapeutics saw its share prices rise by 19.53 percent on Thursday to close at ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback